252 related articles for article (PubMed ID: 11290585)
81. CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.
Mandoli A; Singh AA; Jansen PW; Wierenga AT; Riahi H; Franci G; Prange K; Saeed S; Vellenga E; Vermeulen M; Stunnenberg HG; Martens JH
Leukemia; 2014 Apr; 28(4):770-8. PubMed ID: 24002588
[TBL] [Abstract][Full Text] [Related]
82. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation.
Kitabayashi I; Yokoyama A; Shimizu K; Ohki M
EMBO J; 1998 Jun; 17(11):2994-3004. PubMed ID: 9606182
[TBL] [Abstract][Full Text] [Related]
83. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation.
Elagib KE; Racke FK; Mogass M; Khetawat R; Delehanty LL; Goldfarb AN
Blood; 2003 Jun; 101(11):4333-41. PubMed ID: 12576332
[TBL] [Abstract][Full Text] [Related]
84. Role of AML1/Runx1 in the pathogenesis of hematological malignancies.
Kurokawa M; Hirai H
Cancer Sci; 2003 Oct; 94(10):841-6. PubMed ID: 14556655
[TBL] [Abstract][Full Text] [Related]
85. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.
Yergeau DA; Hetherington CJ; Wang Q; Zhang P; Sharpe AH; Binder M; Marín-Padilla M; Tenen DG; Speck NA; Zhang DE
Nat Genet; 1997 Mar; 15(3):303-6. PubMed ID: 9054947
[TBL] [Abstract][Full Text] [Related]
86. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
Peterson LF; Lo MC; Okumura AJ; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
[TBL] [Abstract][Full Text] [Related]
87. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
88. Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes.
Leroy H; Roumier C; Grardel-Duflos N; Macintyre E; Lepelley P; Fenaux P; Preudhomme C
Blood; 2002 May; 99(10):3848-50. PubMed ID: 11986246
[TBL] [Abstract][Full Text] [Related]
89. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
[TBL] [Abstract][Full Text] [Related]
90. CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium.
Yan J; Liu Y; Lukasik SM; Speck NA; Bushweller JH
Nat Struct Mol Biol; 2004 Sep; 11(9):901-6. PubMed ID: 15322525
[TBL] [Abstract][Full Text] [Related]
91. The role of CBFbeta in AML1-ETO's activity.
Park S; Speck NA; Bushweller JH
Blood; 2009 Sep; 114(13):2849-50. PubMed ID: 19779050
[No Abstract] [Full Text] [Related]
92. Functional mutagenesis of AML1/RUNX1 and PEBP2 beta/CBF beta define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain.
Nagata T; Werner MH
J Mol Biol; 2001 Apr; 308(2):191-203. PubMed ID: 11327761
[TBL] [Abstract][Full Text] [Related]
93. Transforming properties of the leukemic inv(16) fusion gene CBFB-MYH11.
Hajra A; Liu PP; Collins FS
Curr Top Microbiol Immunol; 1996; 211():289-98. PubMed ID: 8585960
[No Abstract] [Full Text] [Related]
94. The leukemic core binding factor beta-smooth muscle myosin heavy chain (CBF beta-SMMHC) chimeric protein requires both CBF beta and myosin heavy chain domains for transformation of NIH 3T3 cells.
Hajra A; Liu PP; Wang Q; Kelley CA; Stacy T; Adelstein RS; Speck NA; Collins FS
Proc Natl Acad Sci U S A; 1995 Mar; 92(6):1926-30. PubMed ID: 7892201
[TBL] [Abstract][Full Text] [Related]
95. Haploinsufficiency of Runx1 results in the acceleration of mesodermal development and hemangioblast specification upon in vitro differentiation of ES cells.
Lacaud G; Kouskoff V; Trumble A; Schwantz S; Keller G
Blood; 2004 Feb; 103(3):886-9. PubMed ID: 14525762
[TBL] [Abstract][Full Text] [Related]
96. Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos.
Maki K; Yamagata T; Asai T; Yamazaki I; Oda H; Hirai H; Mitani K
Blood; 2005 Sep; 106(6):2147-55. PubMed ID: 15914564
[TBL] [Abstract][Full Text] [Related]
97. AML1 interconnected pathways of leukemogenesis.
Michaud J; Scott HS; Escher R
Cancer Invest; 2003; 21(1):105-36. PubMed ID: 12643014
[TBL] [Abstract][Full Text] [Related]
98. The core-binding factor leukemias: lessons learned from murine models.
Downing JR
Curr Opin Genet Dev; 2003 Feb; 13(1):48-54. PubMed ID: 12573435
[TBL] [Abstract][Full Text] [Related]
99. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.
Cunningham L; Finckbeiner S; Hyde RK; Southall N; Marugan J; Yedavalli VR; Dehdashti SJ; Reinhold WC; Alemu L; Zhao L; Yeh JR; Sood R; Pommier Y; Austin CP; Jeang KT; Zheng W; Liu P
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14592-7. PubMed ID: 22912405
[TBL] [Abstract][Full Text] [Related]
100. Cbfbeta-SMMHC impairs differentiation of common lymphoid progenitors and reveals an essential role for RUNX in early B-cell development.
Kuo YH; Gerstein RM; Castilla LH
Blood; 2008 Feb; 111(3):1543-51. PubMed ID: 17940206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
